Swipe for more

• January 22, 2026

  bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies

  bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

  Read more
  

• December 04, 2025

  bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

  bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS® Equine INSULIN and VIDAS® Equine ACTH.

  Read more
  

• November 05, 2025

  Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug-resistant tuberculosis

  Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.

  Read more